Hemogenyx Pharmaceuticals Plc HEMO.L · Stock Open Hemogenyx Pharmaceuticals Plc in new tab
Hemogenyx Pharmaceuticals Plc Analysis (HEMO.L)
Is Hemogenyx Pharmaceuticals Plc a good investment? Hemogenyx Pharmaceuticals Plc (HEMO.L) is currently trading at 736.00 GBX.
Earnings Schedule: Hemogenyx Pharmaceuticals Plc is expected to release its next earnings report on April 27, 2026.
Investor FAQ
Does Hemogenyx Pharmaceuticals Plc pay a dividend?
No, it does not currently pay a dividend.
What asset class is Hemogenyx Pharmaceuticals Plc?
Hemogenyx Pharmaceuticals Plc is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.
When is the next earnings date?
The next earnings date is projected to be April 27, 2026.
Company Profile
Hemogenyx Pharmaceuticals Plc, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies and treatments for blood cancer. The company's lead product candidate is the HEMO-CAR-T therapy for the treatment and potential cure for relapsed and/or refractory acute myeloid leukemia. It also develops chimeric bait receptor to treat COVID-19 virus, as well as to treat brain cancers and/or certain neurodegenerative diseases; and CDX bi-specific antibody which eliminates hematopoietic stem cells/hematopoietic progenitors in a patient using bi-specific antibodies; and cell therapy products for bone marrow/hematopoietic stem cell transplantation. Hemogenyx Pharmaceuticals Plc was incorporated in 2013 and is headquartered in London, the United Kingdom.
Community Discussion